Modulation of vinblastine resistance with cyclosporine

A phase I study

Brian L. Samuels, Rosemarie Mick, Nicholas J. Vogelzang, Stephanie F. Williams, Richard L. Schilsky, Ahmad Safa, Sheila M. O'Brien, Mark J. Ratain

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Objective: Tumor cell resistance is a major cause of failure to cure advanced malignancies. Multidrug resistance is thought to be an important mechanism of such resistance. Our aims were to identify doses of cyclosporine that would achieve blood levels effective in modulating multidrug resistance to vinblastine and to evaluate the toxicities and maximum tolerated dose of cyclosporine when administered in conjunction with vinblastine. Methods: We conducted a phase I trial of vinblastine and escalating doses of cyclosporine. Cyclosporine was given by continuous intravenous infusion over 120 hours and vinblastine was administered by continuous infusion from hour 12 to hour 108. Sixty-two patients entered the trial, of whom 60 were evaluable. Results: Cyclosporine was escalated from 1 to 15.6 mg/kg/day. Vinblastine doses were reduced to 1.6 and then 1.2 mg/m2/day because of increasing vinblastine toxicity at higher cyclosporine doses. The maximum tolerated dose of cyclosporine at 1.2 mg/m2/day vinblastine was 12.5 mg/kg/day; at this dose level, mean blood cyclosporine level was 1.25 ± 0.41 μmol/L. Significant nephrotoxicity was observed at higher cyclosporine doses in two of four patients. Nephrotoxicity was not significant at doses at or lower than this maximum tolerated dose and was not cyclosporine dose dependent. Myelosuppression, neurotoxicity, and transient hyperbilirubinemia were observed and were cyclosporine dose dependent. Conclusions: Cyclosporine by continuous infusion may be safely given in high doses concurrently with continuous-infusion vinblastine. Plasma levels of cyclosporine ≥1 μmol/L can be sustained during vinblastine administration. No sustained effect on T-cell subsets was observed. Vinblastine toxicity is enhanced by cyclosporine in a dose-dependent fashion and correlates with cyclosporine-induced hyperbilirubinemia.

Original languageEnglish (US)
Pages (from-to)421-429
Number of pages9
JournalClinical Pharmacology and Therapeutics
Volume54
Issue number4
StatePublished - Oct 1993
Externally publishedYes

Fingerprint

Vinblastine
Cyclosporine
Maximum Tolerated Dose
Hyperbilirubinemia
Multiple Drug Resistance
T-Lymphocyte Subsets
Intravenous Infusions

ASJC Scopus subject areas

  • Pharmacology

Cite this

Samuels, B. L., Mick, R., Vogelzang, N. J., Williams, S. F., Schilsky, R. L., Safa, A., ... Ratain, M. J. (1993). Modulation of vinblastine resistance with cyclosporine: A phase I study. Clinical Pharmacology and Therapeutics, 54(4), 421-429.

Modulation of vinblastine resistance with cyclosporine : A phase I study. / Samuels, Brian L.; Mick, Rosemarie; Vogelzang, Nicholas J.; Williams, Stephanie F.; Schilsky, Richard L.; Safa, Ahmad; O'Brien, Sheila M.; Ratain, Mark J.

In: Clinical Pharmacology and Therapeutics, Vol. 54, No. 4, 10.1993, p. 421-429.

Research output: Contribution to journalArticle

Samuels, BL, Mick, R, Vogelzang, NJ, Williams, SF, Schilsky, RL, Safa, A, O'Brien, SM & Ratain, MJ 1993, 'Modulation of vinblastine resistance with cyclosporine: A phase I study', Clinical Pharmacology and Therapeutics, vol. 54, no. 4, pp. 421-429.
Samuels BL, Mick R, Vogelzang NJ, Williams SF, Schilsky RL, Safa A et al. Modulation of vinblastine resistance with cyclosporine: A phase I study. Clinical Pharmacology and Therapeutics. 1993 Oct;54(4):421-429.
Samuels, Brian L. ; Mick, Rosemarie ; Vogelzang, Nicholas J. ; Williams, Stephanie F. ; Schilsky, Richard L. ; Safa, Ahmad ; O'Brien, Sheila M. ; Ratain, Mark J. / Modulation of vinblastine resistance with cyclosporine : A phase I study. In: Clinical Pharmacology and Therapeutics. 1993 ; Vol. 54, No. 4. pp. 421-429.
@article{12909a95a5fb4f33a65a41f28ffde0e7,
title = "Modulation of vinblastine resistance with cyclosporine: A phase I study",
abstract = "Objective: Tumor cell resistance is a major cause of failure to cure advanced malignancies. Multidrug resistance is thought to be an important mechanism of such resistance. Our aims were to identify doses of cyclosporine that would achieve blood levels effective in modulating multidrug resistance to vinblastine and to evaluate the toxicities and maximum tolerated dose of cyclosporine when administered in conjunction with vinblastine. Methods: We conducted a phase I trial of vinblastine and escalating doses of cyclosporine. Cyclosporine was given by continuous intravenous infusion over 120 hours and vinblastine was administered by continuous infusion from hour 12 to hour 108. Sixty-two patients entered the trial, of whom 60 were evaluable. Results: Cyclosporine was escalated from 1 to 15.6 mg/kg/day. Vinblastine doses were reduced to 1.6 and then 1.2 mg/m2/day because of increasing vinblastine toxicity at higher cyclosporine doses. The maximum tolerated dose of cyclosporine at 1.2 mg/m2/day vinblastine was 12.5 mg/kg/day; at this dose level, mean blood cyclosporine level was 1.25 ± 0.41 μmol/L. Significant nephrotoxicity was observed at higher cyclosporine doses in two of four patients. Nephrotoxicity was not significant at doses at or lower than this maximum tolerated dose and was not cyclosporine dose dependent. Myelosuppression, neurotoxicity, and transient hyperbilirubinemia were observed and were cyclosporine dose dependent. Conclusions: Cyclosporine by continuous infusion may be safely given in high doses concurrently with continuous-infusion vinblastine. Plasma levels of cyclosporine ≥1 μmol/L can be sustained during vinblastine administration. No sustained effect on T-cell subsets was observed. Vinblastine toxicity is enhanced by cyclosporine in a dose-dependent fashion and correlates with cyclosporine-induced hyperbilirubinemia.",
author = "Samuels, {Brian L.} and Rosemarie Mick and Vogelzang, {Nicholas J.} and Williams, {Stephanie F.} and Schilsky, {Richard L.} and Ahmad Safa and O'Brien, {Sheila M.} and Ratain, {Mark J.}",
year = "1993",
month = "10",
language = "English (US)",
volume = "54",
pages = "421--429",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Modulation of vinblastine resistance with cyclosporine

T2 - A phase I study

AU - Samuels, Brian L.

AU - Mick, Rosemarie

AU - Vogelzang, Nicholas J.

AU - Williams, Stephanie F.

AU - Schilsky, Richard L.

AU - Safa, Ahmad

AU - O'Brien, Sheila M.

AU - Ratain, Mark J.

PY - 1993/10

Y1 - 1993/10

N2 - Objective: Tumor cell resistance is a major cause of failure to cure advanced malignancies. Multidrug resistance is thought to be an important mechanism of such resistance. Our aims were to identify doses of cyclosporine that would achieve blood levels effective in modulating multidrug resistance to vinblastine and to evaluate the toxicities and maximum tolerated dose of cyclosporine when administered in conjunction with vinblastine. Methods: We conducted a phase I trial of vinblastine and escalating doses of cyclosporine. Cyclosporine was given by continuous intravenous infusion over 120 hours and vinblastine was administered by continuous infusion from hour 12 to hour 108. Sixty-two patients entered the trial, of whom 60 were evaluable. Results: Cyclosporine was escalated from 1 to 15.6 mg/kg/day. Vinblastine doses were reduced to 1.6 and then 1.2 mg/m2/day because of increasing vinblastine toxicity at higher cyclosporine doses. The maximum tolerated dose of cyclosporine at 1.2 mg/m2/day vinblastine was 12.5 mg/kg/day; at this dose level, mean blood cyclosporine level was 1.25 ± 0.41 μmol/L. Significant nephrotoxicity was observed at higher cyclosporine doses in two of four patients. Nephrotoxicity was not significant at doses at or lower than this maximum tolerated dose and was not cyclosporine dose dependent. Myelosuppression, neurotoxicity, and transient hyperbilirubinemia were observed and were cyclosporine dose dependent. Conclusions: Cyclosporine by continuous infusion may be safely given in high doses concurrently with continuous-infusion vinblastine. Plasma levels of cyclosporine ≥1 μmol/L can be sustained during vinblastine administration. No sustained effect on T-cell subsets was observed. Vinblastine toxicity is enhanced by cyclosporine in a dose-dependent fashion and correlates with cyclosporine-induced hyperbilirubinemia.

AB - Objective: Tumor cell resistance is a major cause of failure to cure advanced malignancies. Multidrug resistance is thought to be an important mechanism of such resistance. Our aims were to identify doses of cyclosporine that would achieve blood levels effective in modulating multidrug resistance to vinblastine and to evaluate the toxicities and maximum tolerated dose of cyclosporine when administered in conjunction with vinblastine. Methods: We conducted a phase I trial of vinblastine and escalating doses of cyclosporine. Cyclosporine was given by continuous intravenous infusion over 120 hours and vinblastine was administered by continuous infusion from hour 12 to hour 108. Sixty-two patients entered the trial, of whom 60 were evaluable. Results: Cyclosporine was escalated from 1 to 15.6 mg/kg/day. Vinblastine doses were reduced to 1.6 and then 1.2 mg/m2/day because of increasing vinblastine toxicity at higher cyclosporine doses. The maximum tolerated dose of cyclosporine at 1.2 mg/m2/day vinblastine was 12.5 mg/kg/day; at this dose level, mean blood cyclosporine level was 1.25 ± 0.41 μmol/L. Significant nephrotoxicity was observed at higher cyclosporine doses in two of four patients. Nephrotoxicity was not significant at doses at or lower than this maximum tolerated dose and was not cyclosporine dose dependent. Myelosuppression, neurotoxicity, and transient hyperbilirubinemia were observed and were cyclosporine dose dependent. Conclusions: Cyclosporine by continuous infusion may be safely given in high doses concurrently with continuous-infusion vinblastine. Plasma levels of cyclosporine ≥1 μmol/L can be sustained during vinblastine administration. No sustained effect on T-cell subsets was observed. Vinblastine toxicity is enhanced by cyclosporine in a dose-dependent fashion and correlates with cyclosporine-induced hyperbilirubinemia.

UR - http://www.scopus.com/inward/record.url?scp=0027365896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027365896&partnerID=8YFLogxK

M3 - Article

VL - 54

SP - 421

EP - 429

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 4

ER -